Site icon pharmaceutical daily

Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases

BusinessWire

Data from multiple studies, including results in the outpatient administration setting and using machine learning technology, evaluating potential of CAR T liso-cel in relapsed and refractory large b-cell lymphoma

Data evaluating CC-486 as maintenance therapy that improves overall survival in acute myeloid leukemia, including analysis of Health-Related Quality of Life

Longer-term efficacy and safety analyses for Reblozyl in beta thalassemia from Phase 3 BELIEVE study 

Pivotal data from KarMMa study on ide-cel, a potential first-in-class BCMA CAR T being developed with bluebird bio in triple-class exposed, relapsed and refractory multiple myeloma patients

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BELIEVE—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its hematology portfolio at the 25 th European Hematology Association (EHA) Annual Congress, which will take place virtually from June 11-14, 2020. Data from nearly 60 company-sponsored studies will be featured, highlighting the company’s innovative approaches to treating blood cancers and other diseases.

In relapsed and refractory large B-cell lymphoma, key studies include analyses evaluating the potential of lisocabtagene maraleucel (liso-cel) treatment in the outpatient setting and data demonstrating the use of machine learning.

In leukemia and myeloid diseases, additional analyses from the QUAZAR AML-001 pivotal Phase 3 study evaluating CC-486 maintenance therapy in acute myeloid leukemia will be presented, in addition to efficacy and safety analyses from the Phase 3 BELIEVE and MEDALIST studies of Reblozyl, a potential first-in-class erythroid maturation agent (EMA) in Europe, in beta thalassemia and lower-risk myelodysplastic syndromes associated anemias, respectively.

In multiple myeloma, pivotal trial results from the KarMMa study of idecabtagene vicleucel (ide-cel; bb2121), a potential first-in-class B-cell maturation antigen (BCMA) -directed chimeric antigen receptor (CAR) T in multiple myeloma being developed with bluebird bio, will be presented, supporting its potential in heavily pre-treated patients with relapsed and refractory multiple myeloma (RRMM). These include translational and correlative data regarding BCMA expression, response and relapse, and analyses on Quality of Life, outcomes and healthcare utilization in patients with RRMM. Updated data from the EVOLVE Phase 1 study of orva-cel (orvacabtagene autoleucel), a fully human BCMA CAR T being developed by Juno Therapeutics, a Bristol-Myers Squibb company, in heavily pre-treated multiple myeloma patients will also be presented. Additionally, clinical data assessing the safety and efficacy of CC-93269, a 2+1 BCMA T cell engager (TCE), will be presented in patients with heavily pre-treated RRMM, as well as data for CC-92480, a novel CELMoD agent evaluated in combination with dexamethasone in patients with RRMM.

“Although we are not able to gather together in person at EHA this year, we still look forward to presenting data on therapeutic approaches that reinforce our commitment to advancing potential treatment options for people living with difficult-to-treat blood diseases,” said Samit Hirawat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb. “These data, spanning a diverse range of blood diseases provide new and important insights into the potential of our therapies in areas of high unmet need.”

Summary of Presentations:

Selected Bristol Myers Squibb studies at the 25th EHA Virtual Annual Congress include:

Beta Thalassemia

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myelofibrosis

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational chimeric antigen receptor (CAR) T-cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering potential new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb company and Juno Therapeutics, a Bristol-Myers Squibb company.

Cautionary Statement Regarding Forward-Looking Statements

Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts

Media Inquiries:
media@bms.com
609-252-3345

Rose Weldon

rose.weldon@bms.com

Investors:
Tim Power

609-252-7509

timothy.power@bms.com

Nina Goworek

908-673-9711

nina.goworek@bms.com

Exit mobile version